The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a market size of USD 24.6 Billion by 2032 growing at a CAGR of 18.5% from ...

Introduction: The DNA of a Biotech BoomThe global plasmid DNA manufacturing market is entering a transformative era, driven by revolutionary advancements in gene therapy, cancer immunotherapy, DNA ...

Looking around, you might not realize it, but corn is everywhere. In one form or another, it's in the cereals in your ...

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 ...

ProBio, a global contract development and manufacturing organization (CDMO), announced that it will present six poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th ...

IMNN-001, based on the company’s proprietary TheraPlas® technology platform, is an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system, enabling cell ...

Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved safety profile of Aldveron's ...

Following in the footsteps of several pharma companies, life sciences giant Thermo Fisher is doubling down on investments at ...

Plasmid vectors pET11a-link-NGFP and pMRBAD ... before plating on kanamycin-containing media. Purify the vector products by electrophoresis through 0.8–1% agarose and determine the concentration ...

As the exclusive CDMO partner for this program, Porton Advanced provided comprehensive process development and manufacturing services, including plasmid, lentiviral vectors and final CAR-T cell ...

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has signed an ...